Symbols

IVVD

Invivyd·NASDAQ

--(--)

IVVD fundamentals

IVVD Q4 2025 Earnings

Invivyd (IVVD) released its earnings on Mar 5, 2026: revenue was 17.20M (YoY +24.64%), met estimates; EPS was 0.02 (YoY +113.33%), beat estimates.

Revenue / YoY

17.20M

+24.64%

EPS / YoY

0.02

+113.33%

Report date

Mar 5, 2026

IVVD Earnings Call Summary for Q4,2025

Clinical Momentum: VYD2311 trial on track with potential resize in April; RSV antibody shows competitive potential; measles program update expected in H1 2026.
Commercial Strength: PEMGARDA revenue up 31% QoQ, 77% reorder rate, and 15,000+ GPO sites highlight strong provider adoption.
Financial Stability: $226.7M cash post-$200M funding, supporting mid-2026 VYD2311 data readout.
Strategic Expansion: Targeting broader populations with next-gen antibodies, including pediatric and outbreak use cases.

Earnings

EPS

Revenue

Revenue & Expenses

IVVD has released its 2025 Q4 earnings report, with revenue of 17.21M, reflecting a YoY change of 24.51%, and net profit of -11.07M, showing a YoY change of 39.98%. The Sankey diagram below clearly presents IVVD's revenue sources and cost distribution.

Key Indicators

Invivyd (IVVD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Invivyd (IVVD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Invivyd (IVVD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Invivyd (IVVD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown